Effect of Dyslipidemia Therapy on Creatinine Kinase Activity Level in Patients with Heart Disease

Waode Dila Sulistian, Muhamad Ro’biul Fuadi, Soebagijo Poegoeh Edijanto, Mochammad Yusuf

Abstract


Cardiovascular disease remains a significant health problem in the Asia Pacific region. Several studies have found that dyslipidemia is a cause of morbidity and mortality and requires high medical costs. Dyslipidemia is a risk factor for atherosclerosis. The most widely used therapy for dyslipidemia is statins. Statins often cause muscle disorders such as myalgia, myopathy, and rhabdomyolysis, which can cause death. A prospective cohort study design was carried out at Airlangga University Hospital, Surabaya, from April to November 2019. A total of 26 sample pairs containing 13 samples were treated with Atorvastatin, and 13 samples were treated with Simvastatin. The subjects were examined for the creatinine kinase activity level using enzymatic methods. The mean creatinine kinase levels in the atorvastatin group before and after treatment was 105.71 IU/L and 100.03 IU/L, respectively, because the subjects were diagnosed with acute coronary syndromes and blood was collected during acute conditions. Median creatinine kinase levels in the Simvastatin group were 85.5 IU/L before therapy and 118.1 IU/L after therapy, indicating significant differences in creatinine kinase levels before and after treatment. Simvastatin is very susceptible to certain drug interactions that can increase the concentration of statins in the serum. There were differences in levels of creatinine kinase activity before and after Simvastatin therapy but not Atorvastatin.

Keywords


Dyslipidemia, Atorvastatin, Simvastatin, creatinine kinase, enzymatic methods

Full Text:

PDF

References


Moor VJA, Amougou SN, Ombotto S, Ntone F,

Wouamba DE, Nonga BN. Dyslipidemia in patients

with a cardiovascular risk and disease at the University

Teaching Hospital of Yaoundé, Cameroon.

International Journal of Vascular Medicine, Hindawi

Publishing Corporation, 2017; 2017: 1-5.

Lin CF, Chang YH, Chien SC, Lin YH, Yeh HY.

Epidemiology of dyslipidemia in the Asia Pacific

Region. International Journal of Gerontology, 2018;

(1): 2–6.

Carreras ET, Polk DM. Dyslipidemia; Current therapies

and guidelines for treatment. US Cardiology Review,

; 11(1): 10-5.

Ramkumar S, Raghunath A, Raghunath S. Statin

therapy: Review of safety and potential side effects.

Acta Cardiol Sin, 2016; 32(6): 631-639.

Rosenson RS, Baker S, Banach M, Borrow KM, Braun LT,

et al. Optimizing cholesterol treatment in patients with

muscle complaints. Journal of American College of

Cardiology, 2017; 70(10): 1290–1301.

Stroes ES, Thompson PD, Corsini A, Vladutiu GD,

Raal FJ, et al. Statin associated muscle symptoms:

Impact on Statin therapy-European atherosclerosis

society consensus panel statement on assessment,

etiology, and management. European Heart Journal,

; 36: 1012-1022.

Nogueira AA, Strunz CM, Takada JY, Mansur AP.

Biochemical markers of muscle damage and high

serum concentration of creatine kinase in patients on

statin therapy. Biomarkers in Medicine, 2019; 13: 8.

Muhibbah, Wahid A, Agustina R, Illiandri O. Karakteristik

pasien sindrom koroner akut pada pasien rawat inap

Ruang Tulip di RSUD Ulin Banjarmasin. Indonesian

Journal for Health Sciences, 2019; 3(1): 6–12.

Kawamoto KR, Davis MB, Duvernoy CS. Acute coronary

syndromes: Differences in men and women. Curr

Atheroscler Rep, 2016; 18: 73.

Nuzzo A, Rossi R, Modena MG. Hypertension alone or

related to the metabolic syndrome in post-menopausal

women. Expert Review of Cardiovascular Therapy,

; 8(11): 1541–1548.

Mirghani HO. Age-related differences in acute

coronary syndrome presentation and in-hospital

outcomes: A cross-sectional comparative study. Pan

African Medical Journal, 2016; 24(337): 1–5.

Nkoke C, Makoge C, Dzudie A, Mfeukeu LK, Luchuo EB,

et al. A predominance of hypertensive heart disease

among patients with cardiac disease in Buea, a

semi-urban setting, South West Region of Cameroon.

BMC Research Notes, BioMed Central, 2017; 10(684):

–6.

Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension,

and cardiovascular disease: Clinical insights and

vascular mechanisms. Canadian Journal of Cardiology,

; 34(5): 575–584.

Zhou M, Liu J, Hao Y, Liu J, Huo Y, et al. Prevalence and

in-hospital outcomes of diabetes among patients with

acute coronary syndrome in China: Findings from

the improving care for cardiovascular disease in

China-acute coronary syndrome project. Cardiovasc

Diabetol, 2018; (17): 147.

Kjeldsen SE. Hypertension and cardiovascular risk:

General aspects. Pharmacological Research, Elsevier

Ltd, 2017; 12: 95–99.

Ralapanawa U, Kumarasiri PVR, Jayawickreme KP,

Kumarihamy P, Wijeratne Y, et al. Epidemiology and

risk factors of patients with types of acute coronary

syndrome presenting to a tertiary care hospital in

Sri Lanka. BMC Cardiovascular Disorders, 2019;

(229): 1–9.

Danese E, Montagnana M. An historical approach to

the diagnostic biomarkers of acute coronary

syndrome. Annals of Translational Medicine, 2016;

(8): 1–11.

Morales D, Parker B, Thompson PD. Increases CK level

on high doses of Atorvastatin are related to decreases

in muscle strength but do not predict myalgia.

American Heart Association Journal, 2018; 126(21):

Wang YC, Hsieh TC, Chou CL, Wu JL, Fang TC. Risks of

adverse events following prescription of statins and

calcium channel blockers. Medicine (Baltimore), 2016;

(2): e2487.

Ward NC, Watts GF, Eckel RH. Statin toxicity.

Circulation Research, 2019; 124: 328-350.




DOI: http://dx.doi.org/10.24293/ijcpml.v27i2.1631

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.